UTHR - ユナイテッド・セラピュ―ティクス （United Therapeutics Corporation） ユナイテッド・セラピュ―ティクスUTHRのチャート
UTHRの企業情報
| symbol | UTHR |
|---|---|
| 会社名 | United Therapeutics Corp （ユナイテッド・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ユナイテッド・セラピューティクス（United Therapeutics Corporation）は慢性と命にかかわる症状を持つ患者の満たされていない医学的ニーズに応じた薬剤の開発・商品化に従事するバイオ企業。同社の治療薬品と薬品候補はプロスタサイクリン類縁体、ホスホジエステラーゼ5（PDE-5）阻害薬、モノクローナル抗体（MAb）、糖鎖に関連した抗ウイルス剤、細胞療法及び移植のためのエンジニア肺と肺組織を含む。プロスタサイクリンアナログは、プロスタサイクリンの安定合成形態である。同社の製品はRemodulin（トレプロスチニル）インジェクションである。PDE-5阻害剤は、細胞における環状グアノシン一リン酸（cGMP）の分解を阻害するように作用する。PDE-5阻害剤は肺動脈性肺高血圧症（PAH）の治療のために1日1回経口投与治療薬であるAdcirca（タダラフィル）錠。MAbは癌細胞にある腫瘍関連抗原を標的として癌細胞に対する患者の免疫系を活性化して作用する。 ユナイテッド・セラピュ―ティクスは、米国のバイオテクノロジ―企業。慢性・生命に係わる状態の患者に革新的な製品を開発・商業化することに焦点を当てる。製品は、プロスタサイクリン・アナログ、ホスホジエステラ―ゼタイプ5阻害剤、モノクロ―ナル抗体、糖鎖生物学抗ウイルス剤などがあり、肺動脈高血圧、癌、ウイルス性疾患などの治療への研究をする。 United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture and our bioinformatics leadership. We also believe that our determination to be responsible citizens - having a positive impact on patients, the environment and society - will sustain our success in the long term. Through our wholly-owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company. |
| 本社所在地 | 1040 Spring Street Silver Spring MD 20910 USA |
| 代表者氏名 | Martine A. Rothblatt マルティンA.ロスブラット |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 301-608-9292 |
| 設立年月日 | 35217 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 1999年 |
| 従業員数 | 800人 |
| url | www.unither.com |
| nasdaq_url | https://www.nasdaq.com/symbol/uthr |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 118.5 |
| 終値（lastsale） | 126.77 |
| 時価総額（marketcap） | 5522484806.02 |
| 時価総額 | 時価総額（百万ドル） 5287.68 |
| 売上高 | 売上高（百万ドル） 1743.9 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 4324.68 |
| 当期純利益 | 当期純利益（百万ドル） 783.70000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 United Therapeutics Corporation revenues increased 2% to $833.7M. Net income increased from $122.6M to $417.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Impairment of cost method investment decrease from $46.5M (expense) to $0K Share-based compensation increase from $12.2M to $56M (income). |
UTHRのテクニカル分析
UTHRのニュース
Top 5 4th Quarter Trades of TOBAM 2023/02/02 20:00:16 GuruFocus
Related Stocks: EA , UTHR , BDX , TTWO , LVS ,
Liquidia stock gains after PTAB denies United Therapeutics request for patent rehearing 2023/02/02 19:03:54 Seeking Alpha
Liquidia (LQDA) rose 6.3% after a U.S. patent court denied a request for a rehearing of the United Therapeutics (UTHR) patent invalidation decision. The Patent Trial and Appeal Board…
United Therapeutics Corp. PT Raised to $330 at UBS 2023/02/02 14:22:15 Investing.com
https://www.investing.com/news/pro/united-therapeutics-corp-pt-raised-to-330-at-ubs-432SI-2994289
This Insider Just Sold Shares of United Therapeutics Corp 2023/01/25 18:30:07 GuruFocus
Related Stocks: UTHR ,
United Therapeutics (UTHR) Presents At 41st Annual Healthcare Conference - Slideshow (NASDAQ:UTHR) 2023/01/20 12:49:10 Seeking Alpha
The following slide deck was published by United Therapeutics Corporation in conjunction with this event.
United Therapeutics Announces First Patient Enrolled in Phase 3 TETON 2 Study of Tyvaso in Patients With Idiopathic Pulmonary Fibrosis 2022/10/11 10:00:00 Wallstreet:Online
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the first patient has enrolled in the phase 3 TETON 2 study which will evaluate Tyvaso in 396 adult patients with idiopathic pulmonary fibrosis (IPF) at sites outside the United States and Canada. This second registration study is part of the broader global TETON program evaluating Tyvaso for the
Argus Positive on United Therapeutics Corp. , ''Discounted price offers buying opportunity'' 2022/09/22 11:04:02 Investing.com
https://www.investing.com/news/pro/argus-positive-on-united-therapeutics-corp--discounted-price-offers-buying-opportunity-432SI-2897043
United Therapeutics initiated at outperform at Wedbush on growth and innovation (UTHR) 2022/09/19 15:01:28 Seeking Alpha
Wedbush has initiated United Therapeutics (UTHR) with an outperform rating saying that the pharma, is poised for growth and has a strong pipeline.
Wedbush Assumes United Therapeutics Corp. at Outperform 2022/09/19 10:52:01 Investing.com
https://www.investing.com/news/pro/wedbush-assumes-united-therapeutics-corp-at-outperform-432SI-2894675
Was anything positive for United Therapeutics Corporation (UTHR) stock last session? 2022/09/01 12:48:00 US Post News
In Wednesday’s session, United Therapeutics Corporation (NASDAQ:UTHR) marked $226.62 per share, up from $218.97 in the previous session. While United Therapeutics Corporation has overperformed by 3.49%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, UTHR rose by 5.46%, with highs and lows ranging from $245.48 to […]
Argus Positive on United Therapeutics Corp. , ''Discounted price offers buying opportunity'' 2022/09/22 11:04:02 Investing.com
https://www.investing.com/news/pro/argus-positive-on-united-therapeutics-corp--discounted-price-offers-buying-opportunity-432SI-2897043
United Therapeutics initiated at outperform at Wedbush on growth and innovation (UTHR) 2022/09/19 15:01:28 Seeking Alpha
Wedbush has initiated United Therapeutics (UTHR) with an outperform rating saying that the pharma, is poised for growth and has a strong pipeline.
Wedbush Assumes United Therapeutics Corp. at Outperform 2022/09/19 10:52:01 Investing.com
https://www.investing.com/news/pro/wedbush-assumes-united-therapeutics-corp-at-outperform-432SI-2894675
Was anything positive for United Therapeutics Corporation (UTHR) stock last session? 2022/09/01 12:48:00 US Post News
In Wednesday’s session, United Therapeutics Corporation (NASDAQ:UTHR) marked $226.62 per share, up from $218.97 in the previous session. While United Therapeutics Corporation has overperformed by 3.49%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, UTHR rose by 5.46%, with highs and lows ranging from $245.48 to […]
United Therapeutics Prevails in Dry Powder Inhaler Patent Litigation 2022/08/31 22:40:00 Business Wire
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the United States District Court for the District of Delaware issued an opinion in the pending litigation concerning United Therapeutics’ U.S. patents 9,593,066 (the ’066 patent) and 10,716,793 (the ’793 patent). This litigation concerns whether Liquidia Technologies, Inc.’s proposed treprostinil inhalation powder, YutrepiaTM, wou